دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy
Hyeok-HeeLeeMDab?HokyouLeeMDab?So Mi JemmaChoPhDaDong-WookKimPhDcSunghaParkMD, PhDbdHyeon ChangKimMD, PhDab
doi : 10.1016/j.jacc.2021.08.015
Volume 78, Issue 15, 12 October 2021, Pages 1485-1495
Benefits of intensive blood pressure lowering on health outcomes have been demonstrated in high-risk patients. However, little is known about such benefits in patients with left ventricular hypertrophy (LVH).
On-Treatment Hypertension Control in a Real-World Cohort: Lower Blood Pressure Remains Better?
S. AndrewMcCulloughMDaDavid C.GoffJr.MD, PhDbPeter M.OkinMDa
doi : 10.1016/j.jacc.2021.08.014
Volume 78, Issue 15, 12 October 2021, Pages 1496-1498
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT
KazumaOyamaMD, PhDabRobert P.GiuglianoMD, SMaMichael A.BlazingMDcJeong-GunParkPhDaAndrew M.TershakovecMD, MPHdMarc S.SabatineMD, MPHaChristopher P.CannonMDaEugeneBraunwaldMDa
doi : 10.1016/j.jacc.2021.08.011
Volume 78, Issue 15, 12 October 2021, Pages 1499-1507
The 2018 U.S. cholesterol management guideline recommends additional lipid-lowering therapy with ezetimibe for secondary prevention in very high-risk patients with low-density lipoprotein cholesterol (LDL-C) ?70 mg/dL despite maximally tolerated statin.
Treatment Thresholds and ASCVD Risk?
VeraBittnerMD, MSPH
doi : 10.1016/j.jacc.2021.08.029
Volume 78, Issue 15, 12 October 2021, Pages 1508-1510
Biventricular Myocardial Fibrosis and Sudden Death in Patients With Brugada Syndrome
ChrisMilesMBChB, PhDaAngelikiAsimakiPhDaIrina ChisSterMSc, PhDbMichaelPapadakisMDaBelindaGrayMBBS, PhDacdJosephWestabyBMBS, MScaGherardoFinocchiaroMD, PhDaeCarlosBueno-BetiPhDaBodeEnsamMBChBaJoyeeBasuBMBCh, MAaGemmaParry-WilliamsMBChBaHamishMacLachlanMBBSaKhari A.EdwardsMScaDavidJohnsonPhDaMaiteTomeMD, PhDaSanjaySharmaMDaMary N.SheppardMBBCh, MDa?Elijah R.BehrMD, MAa?
doi : 10.1016/j.jacc.2021.08.010
Volume 78, Issue 15, 12 October 2021, Pages 1511-1521
Electrophysiological, imaging, and pathological studies have reported the presence of subtle structural abnormalities in hearts from patients with Brugada syndrome (BrS). However, data concerning disease involvement outside of the right ventricular outflow tract are limited.
Myocardial Histopathology Studies in Brugada Syndrome Decedents: Structural Features of a Presumed Electrical Disease?
BabkenAsatryanMD, PhDKatja E.OdeningMDTobiasReichlinMD
doi : 10.1016/j.jacc.2021.08.016
Volume 78, Issue 15, 12 October 2021, Pages 1522-1524
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
PrakritiGabaMDaDeepak L.BhattMD, MPHaRobert P.GiuglianoMD, SMaPh. GabrielStegMDbMichaelMillerMDcEliot A.BrintonMDdTerry A.JacobsonMDeSteven B.KetchumPhDfRebecca A.JulianoPhDfLixiaJiaoPhDfRalph T.DoyleJr.BAfCraigGranowitzMD, PhDfJean-ClaudeTardifMDgChristie M.BallantyneMDhDuane S.PintoMD, MPHiMatthew J.BudoffMDjC. MichaelGibsonMDi
doi : 10.1016/j.jacc.2021.08.009
Volume 78, Issue 15, 12 October 2021, Pages 1525-1537
REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) randomized statin-treated patients with elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in adjudicated events, including the primary endpoint (cardiovascular [CV] death, myocardial infarction [MI], stroke, coronary revascularization, unstable angina requiring hospitalization) and key secondary endpoint (CV death, MI, stroke) with IPE.
Investigator-Reported Versus Adjudicated Clinical Events: 2 Versions of the Truth??
Stephen J.GreeneMDabJavedButlerMD, MPH, MBAc
doi : 10.1016/j.jacc.2021.08.023
Volume 78, Issue 15, 12 October 2021, Pages 1538-1540
Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function: JACC Technology Corner
BernardDe BruyneMD, PhDab?Nico H.J.PijlsMD, PhDc?EmanueleGallinoroMDadAlessandroCandrevaMDaStephaneFournierMDbDanielle C.J.KeulardsMDcJeroenSonckMDaeMarcelvan’t VeerMS, PhDcfEmanueleBarbatoMD, PhDaeJozefBartunekMD, PhDaMarcVanderheydenMDaEricWyffelsMDaAnnemiekDe VosMDcMohamedEl FarissiMDcPim A.L.ToninoMD, PhDcOlivierMullerMD, PhDbCarlosColletMD, PhDaWilliam F.FearonMDg
doi : 10.1016/j.jacc.2021.08.017
Volume 78, Issue 15, 12 October 2021, Pages 1541-1549
The need for a quantitative and operator-independent assessment of coronary microvascular function is increasingly recognized. We propose the theoretical framework of microvascular resistance reserve (MRR) as an index specific for the microvasculature, independent of autoregulation and myocardial mass, and based on operator-independent measurements of absolute values of coronary flow and pressure. In its general form, MRR equals coronary flow reserve (CFR) divided by fractional flow reserve (FFR) corrected for driving pressures. In 30 arteries, pressure, temperature, and flow velocity measurements were obtained simultaneously at baseline (BL), during infusion of saline at 10 mL/min (rest) and 20 mL/min (hyperemia). A strong correlation was found between continuous thermodilution-derived MRR and Doppler MRR (r = 0.88; 95% confidence interval: 0.72-0.93; P < 0.001). MRR was independent from the epicardial resistance, the lower the FFR value, the greater the difference between MRR and CFR. Therefore, MRR is proposed as a specific, quantitative, and operator-independent metric to quantify coronary microvascular dysfunction.
Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week
Alexander E.SullivanMDaMichael G.NannaMD, MHSbTracy Y.WangMD, MHS, MSccDeepak L.BhattMD, MPHdDominick J.AngiolilloMD, PhDeRoxanaMehranMDfSubhashBanerjeeMDgSarahCantrellMLIShW. SchuylerJonesMDcJennifer A.RymerMDcJeffrey B.WashamPharmDiSunil V.RaoMDcE. MagnusOhmanMDc
doi : 10.1016/j.jacc.2021.08.013
Volume 78, Issue 15, 12 October 2021, Pages 1550-1563
Patients undergoing early surgery after coronary stent implantation are at increased risk for mortality from ischemic and hemorrhagic complications. The optimal antiplatelet strategy in patients who cannot discontinue dual antiplatelet therapy (DAPT) before surgery is unclear. Current guidelines, based on surgical and clinical characteristics, provide risk stratification for bridging therapy with intravenous antiplatelet agents, but management is guided primarily by expert opinion. This review summarizes perioperative risk factors to consider before discontinuing DAPT and reviews the data for intravenous bridging therapies. Published reports have included bridging options such as small molecule glycoprotein IIb/IIIa inhibitors (eptifibatide or tirofiban) and cangrelor, an intravenous P2Y12 inhibitor. However, optimal management of these complex patients remains unclear in the absence of randomized controlled data, without which an argument can be made both for and against the use of perioperative intravenous bridging therapy after discontinuing oral P2Y12 inhibitors. Multidisciplinary risk assessment remains a critical component of perioperative care.
High-Quality Peer Review of Clinical and Translational Research: A Practical Guide
Fred M.KusumotoMDaJohn A.BittlMDbMark A.CreagerMDcHarold L.DauermanMDdAnuradhaLalaMDeMary M.McDermottMDfJustine VarieurTurcoMAgViviany R.TaquetiMD, MPHhACC’s Scientific Publications Committee’s Peer Review Work Group
doi : 10.1016/j.jacc.2021.06.055
Volume 78, Issue 15, 12 October 2021, Pages 1564-1568
Population Health: Intersecting Technology, Data, Health Equity to Achieve Health Care Transformation
DiptiItchhaporiaMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.09.001
Volume 78, Issue 15, 12 October 2021, Pages 1569-1572
Prognostic Role of Pericardial Fat on the Incidence of Heart Failure
StefanoBonapaceMDGiulioMolonMDAlessioMarinelliMDLauraLanzoniMDGiovanniTargherMD
doi : 10.1016/j.jacc.2021.06.053
Volume 78, Issue 15, 12 October 2021, Page e111
Reply: Prognostic Role of Pericardial Fat on the Incidence of Heart Failure
SatishKenchaiahMD, MPHMatthew J.BudoffMDJingzhongDingPhDJ. JeffreyCarrMD, MSCEDavid A.BluemkeMD, PhD
doi : 10.1016/j.jacc.2021.08.008
Volume 78, Issue 15, 12 October 2021, Pages e113-e115
What Is Behind the HbA1c Value?
AtsushiTanakaMD, PhDKoichiNodeMD, PhD
doi : 10.1016/j.jacc.2021.06.054
Volume 78, Issue 15, 12 October 2021, Page e117
Reply: What Is Behind the HbA1c Value?
XavierRosselloPhDBorjaIbanezPhDValentinFusterPhD
doi : 10.1016/j.jacc.2021.08.012
Volume 78, Issue 15, 12 October 2021, Page e119
